Phoenix Biotechnology, Inc.

    Home

    Company

    Research

    Clinical Trial Information

       Clinical Trial Abstract

    News

    Contacts

Research

The Company currently focuses its product pipeline on botanical extracts that are being developed with the Pharmaceutical Development Center at The University of Texas M.D. Anderson Cancer Center. The nature of these products and processes is governed by confidentiality obligations such as those found in the Sponsored Research Agreement between the Company and The University of Texas M.D. Anderson Cancer Center, restricting our ability to make any further public disclosure at this time.

The company has been granted an IND by the U.S. Food and Drug Administration (FDA), and the agent has been entered into a Phase I Clinical Trial at M.D. Anderson Cancer Center. For more information click on the link: “Clinical Trial”

Lead Researcher

Robert A. Newman Ph.D
Professor Emeritus and former Professor of Experimental Therapeutics and Co-Director of the Pharmaceutical Development Center at The University of Texas M.D. Anderson Cancer Center.

Sponsored Research Agreement

The company is in the ninth year of a Sponsored Research Agreement (SRA) with The Pharmaceutical Development Center at The University of Texas M.D. Anderson Cancer Center. The first three years of the SRA were funded by Anviram, Inc. The results of which have been assigned to the Company. Phoenix is funding the fourth through the ninth years of the SRA.

The Principal Investigator is Robert A. Newman, PhD., Professor Emeritus and former Professor of Experimental Therapeutics and Co-Director of the Pharmaceutical Development Center. Under his direction, the Company and the Pharmaceutical Development Center at The University of Texas M.D. Anderson Cancer Center are collaborating on research of oleander extracts in order to determine their therapeutic value against neoplastic disease (cancer) and certain viral diseases such as Hepatitis C.

Presentations:

2011 ASCO Annual Meeting. "Each year ASCO takes a very selective approach to the acceptance of submitted abstracts of new research dealing with cancer and its novel therapies. From those accepted another round of review provides an even smaller number for presentation in an oral format along with discussion. The recent clinical research with PBI-05204 from Phoenix Biotechnology, Inc. was among those chosen for a 2011 ASCO poster discussion group." Robert A. Newman Ph.D.

6th SIO International Conference - Nov. 09

2009 ASCO Annual Meeting

Poster

Publications:

Thirteen peer reviewed journal manuscripts have been published by researchers at M.D. Anderson on oleander extract and oleandrin.

Journal of Neurochemistry, (2011) 119, 805–814; Denise E. Dunn, Dong Ning He, Peiying Yang, Mary Johansen, Robert A. Newman and Donald C. Lo. In vitro and in vivo neuroprotective activity of the cardiac glycoside oleandrin from Nerium oleander in brain slice-based stroke models.

Molecular Cancer Therapeutics
8:2319-2328, (2009); Peiying Yang, David G. Menter, Carrie Cartwright, Diana Chan, Susan Dixon, Milind Suraokar, Gabriela Mendoza, Norma Llansa, and Robert A. Newman. Oleandrin-mediated inhibition of human tumor cell proliferation: Importance of Na,K-ATPase a subunits as drug targets

Molecular Interventions, 8:36-49, (2008); Robert A. Newman, Peiying Yang, Alison D. Pawlus and Keith I. Block. Cardiac Glycosides as Novel Cancer Therapeutic Agents.

Integrative Cancer Therapies, 6(4); 2007; Kondo, Y.; Newman, R.A., et al. Autophagic Cell Death of Human Pancreatic Tumor Cells Mediated by Oleandrin, a Lipid-Soluble Cardiac Glycoside.

Journal of Experimental Therapeutics and Oncology, Vol. 5, pp. 167-181; 2006; Newman, R.A; Yang, P., et al. Oleandrin - Mediated oxidative stress in human melanoma cells.

Journal of Experimental Therapeutics and Oncology
Murine pharmacokinetics and metabolism of oleandrin, a cytotoxic component of Nerium oleander.

Cancer Letters
Enhancement of radiotherapy by oleandrin in a caspase-3 dependent process.

Biochemical Pharmacology
Inhibition of export of fibroblast growth factor-2 (FGF-2) from the prostate cancer cell lines PC3 and DU145 by Anvirzel™ and its cardiac glycoside component, oleandrin.

Journal of Herbal Pharmacotherapy
Composition and Preliminary Pharmacology Studies with Anvirzel™: An Extract of Nerium oleander.

Analytical Chemistry
LC/MS/MS Analyses of an Oleander Extract for Cancer Treatment.

Cancer Research, (2 articles)
Cardiac Glycosides Stimulate Ca²⁺ Increases and Apoptosis in Androgen-independent, Metastatic Human Prostate Adenocarcinoma Cells.

Oleandrin Suppresses Activation of Nuclear Transcription Factor _KB, Activator Protein-1, and C-Jun NH₂-Terminal Kinase.

Anti Cancer
Anvirzel™, an extract of Nerium oleander, induces cell death in human but not murine cancer cells.

Site Map | Privacy & Security | Contact Us | Accessibility | Report Piracy